Published in J Gastroenterol on January 22, 2009
The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol (2011) 0.97
Adjuvant therapy in pancreatic cancer. World J Gastroenterol (2014) 0.90
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol (2014) 0.86
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Cancer burden in the year 2000. The global picture. Eur J Cancer (2001) 10.47
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg (1993) 6.15
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg (1999) 5.58
Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg (1995) 4.17
Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg (1995) 3.42
Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer (1976) 2.63
Patterns of failure after curative resection of pancreatic carcinoma. Cancer (1990) 2.43
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer (2005) 2.32
Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer (2008) 2.19
Optimal multivariate matching before randomization. Biostatistics (2004) 1.85
Recurrence of exocrine pancreatic cancer--local or hepatic? Hepatogastroenterology (1993) 1.45
Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys (1991) 1.30
Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med (2004) 1.18
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg (2006) 1.17
Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet (2001) 1.11
Chemotherapy for pancreatic cancer. N Engl J Med (2004) 1.09
Chemotherapy for pancreatic cancer. N Engl J Med (2004) 0.96
Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. Int J Pancreatol (1992) 0.81
Chemotherapy for pancreatic cancer. N Engl J Med (2004) 0.76
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation (2004) 13.07
The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology (2005) 13.05
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol (2011) 5.46
Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol (2011) 4.61
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis (2008) 3.87
Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol (2008) 3.63
Statistical analysis of the primary outcome in acute stroke trials. Stroke (2012) 3.52
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol (2012) 3.11
Association of race and sex with risk of incident acute coronary heart disease events. JAMA (2012) 3.07
Incident cognitive impairment is elevated in the stroke belt: the REGARDS study. Ann Neurol (2011) 3.06
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke (2013) 2.88
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol (2008) 2.68
Patterns of surgical care of lung cancer patients. Ann Thorac Surg (2005) 2.51
Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis (2011) 2.49
Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol (2002) 2.43
The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35
Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol (2006) 2.32
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem (2009) 2.03
The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer. Cancer (2013) 1.97
Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol (2007) 1.87
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther (2008) 1.83
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.81
Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol (2002) 1.76
NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. J Nutr (2010) 1.74
Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg (2004) 1.71
Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis (2010) 1.71
Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke (2011) 1.69
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem (2003) 1.69
A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol (2012) 1.69
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Both extremes of arterial carbon dioxide pressure and the magnitude of fluctuations in arterial carbon dioxide pressure are associated with severe intraventricular hemorrhage in preterm infants. Pediatrics (2007) 1.64
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke (2011) 1.63
Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). J Am Coll Cardiol (2011) 1.60
Prolongation of QTc and risk of stroke: The REGARDS (REasons for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol (2012) 1.60
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.55
Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension (2011) 1.54
National variation in United States sepsis mortality: a descriptive study. Int J Health Geogr (2010) 1.53
Reduced medication access: a marker for vulnerability in US stroke survivors. Stroke (2007) 1.53
Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation (2013) 1.52
Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens (2011) 1.50
Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation (2010) 1.50
Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident ESRD. Am J Kidney Dis (2011) 1.48
Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke (2010) 1.48
Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke (2011) 1.45
Primary cardiac sarcoma. Ann Thorac Surg (2010) 1.45
Statistical power, the Belmont report, and the ethics of clinical trials. Sci Eng Ethics (2010) 1.44
Second births among teenage mothers: program results and statistical methods. J Adolesc Health (2003) 1.43
Effect of duration and age at exposure to the Stroke Belt on incident stroke in adulthood. Neurology (2013) 1.43
Albuminuria and racial disparities in the risk for ESRD. J Am Soc Nephrol (2011) 1.42
Race and gender differences in 1-year outcomes for community-dwelling stroke survivors with family caregivers. Stroke (2011) 1.42
Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol (2007) 1.40
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res (2012) 1.39
Poverty and racial disparities in kidney disease: the REGARDS study. Am J Nephrol (2010) 1.38
The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proc Natl Acad Sci U S A (2004) 1.36
Caregiving strain and all-cause mortality: evidence from the REGARDS study. J Gerontol B Psychol Sci Soc Sci (2012) 1.35
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2009) 1.34
Stewart-Treves syndrome of the lower extremity. J Clin Oncol (2010) 1.32
Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. Am J Kidney Dis (2011) 1.31
Prevalence of hypertension by duration and age at exposure to the stroke belt. J Am Soc Hypertens (2010) 1.29
Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens (2010) 1.28
Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum (2006) 1.28
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys (2002) 1.28
Factors contributing to global cognitive impairment in heart failure: results from a population-based cohort. J Card Fail (2008) 1.28
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) 1.27
Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys (2011) 1.24
The geographic distribution of obesity in the US and the potential regional differences in misreporting of obesity. Obesity (Silver Spring) (2013) 1.24
Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke (2009) 1.23
Self-reported stroke symptoms without a prior diagnosis of stroke or transient ischemic attack: a powerful new risk factor for stroke. Stroke (2011) 1.23
Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS Cohort Study. Am J Nephrol (2008) 1.22
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol (2011) 1.18
Race and gender differences in perceived caregiver availability for community-dwelling middle-aged and older adults. Gerontologist (2007) 1.18
Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke (2007) 1.17
Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr (2011) 1.16
Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem (2007) 1.16
Quality of life after stroke: a prospective longitudinal study. Qual Life Res (2010) 1.16
Chronic medical conditions and risk of sepsis. PLoS One (2012) 1.16
Postgraduate choices of graduates from medical scientist training programs, 2004-2008. JAMA (2009) 1.15
The confounding of race and geography: how much of the excess stroke mortality among African Americans is explained by geography? Neuroepidemiology (2004) 1.15
Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension (2004) 1.15
Credentialing of surgeons as interventionalists for carotid artery stenting: experience from the lead-in phase of CREST. J Vasc Surg (2004) 1.14